Proto Oncogene Tyrosine Protein Kinase Src - Pipeline Review, H1 2020
Proto Oncogene Tyrosine Protein Kinase Src - Pipeline Review, H1 2020
SUMMARY
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) pipeline Target constitutes close to 18 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The latest report Proto Oncogene Tyrosine Protein Kinase Src - Pipeline Review, H1 2020, outlays comprehensive information on the Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Proto-oncogene tyrosine-protein kinase Src or proto-oncogene c-Src is a non-receptor tyrosine kinase protein that is encoded by the SRC gene. It participates in signaling pathways that control a diverse spectrum of biological activities including gene transcription, immune response, cell adhesion, cell cycle progression, apoptosis, migration, and transformation. Due to functional redundancy between members of the SRC kinase family, identification of the specific role of each SRC kinase is very difficult. It plays a role in the activation of other protein tyrosine kinase (PTK) families. It plays an important role in the regulation of cytoskeletal organization through phosphorylation of specific substrates such as AFAP1.
The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 5, 1, 4 and 2 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Gastrointestinal, Respiratory, Genetic Disorders, Musculoskeletal Disorders and Ophthalmology which include indications Non-Small Cell Lung Cancer, Solid Tumor, Ulcerative Colitis, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Interstitial Lung Fibrosis, Lymphangioleiomyomatosis, Medullary Thyroid Cancer, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Soft Tissue Sarcoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alcohol Addiction, Alzheimer's Disease, Anaplastic Large Cell Lymphoma (ALCL), Angiosarcoma, Bladder Cancer, Breast Cancer, Bronchiolitis Obliterans, Cancer Pain, Central Nervous System (CNS) Tumor, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Fallopian Tube Cancer, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Friedreich Ataxia, Gallbladder Cancer, Gastric Cancer, Gastroesophageal (GE) Junction Carcinomas, Head And Neck Cancer, Hereditary Hemorrhagic Telangiectasia (Osler-Weber-Rendu Disease), Idiopathic Pulmonary Fibrosis, Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Keratoconjunctivitis Sicca (Dry Eye), Lewy Body Dementia, Liver Cancer, Lung Adenocarcinoma, Lung Cancer, Malignant Pleural Mesothelioma, Melanoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Neuroendocrine Tumors, Non-Hodgkin Lymphoma, Parkinson's Disease, Peritoneal Cancer, Pneumoconiosis, Psychosis, Refractory Acute Myeloid Leukemia, Salivary Gland Cancer, Squamous Non-Small Cell Lung Cancer and Uterine Cancer.
Furthermore, this report also reviews key players involved in Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) pipeline Target constitutes close to 18 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The latest report Proto Oncogene Tyrosine Protein Kinase Src - Pipeline Review, H1 2020, outlays comprehensive information on the Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Proto-oncogene tyrosine-protein kinase Src or proto-oncogene c-Src is a non-receptor tyrosine kinase protein that is encoded by the SRC gene. It participates in signaling pathways that control a diverse spectrum of biological activities including gene transcription, immune response, cell adhesion, cell cycle progression, apoptosis, migration, and transformation. Due to functional redundancy between members of the SRC kinase family, identification of the specific role of each SRC kinase is very difficult. It plays a role in the activation of other protein tyrosine kinase (PTK) families. It plays an important role in the regulation of cytoskeletal organization through phosphorylation of specific substrates such as AFAP1.
The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 5, 1, 4 and 2 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Gastrointestinal, Respiratory, Genetic Disorders, Musculoskeletal Disorders and Ophthalmology which include indications Non-Small Cell Lung Cancer, Solid Tumor, Ulcerative Colitis, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Interstitial Lung Fibrosis, Lymphangioleiomyomatosis, Medullary Thyroid Cancer, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Soft Tissue Sarcoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alcohol Addiction, Alzheimer's Disease, Anaplastic Large Cell Lymphoma (ALCL), Angiosarcoma, Bladder Cancer, Breast Cancer, Bronchiolitis Obliterans, Cancer Pain, Central Nervous System (CNS) Tumor, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Fallopian Tube Cancer, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Friedreich Ataxia, Gallbladder Cancer, Gastric Cancer, Gastroesophageal (GE) Junction Carcinomas, Head And Neck Cancer, Hereditary Hemorrhagic Telangiectasia (Osler-Weber-Rendu Disease), Idiopathic Pulmonary Fibrosis, Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Keratoconjunctivitis Sicca (Dry Eye), Lewy Body Dementia, Liver Cancer, Lung Adenocarcinoma, Lung Cancer, Malignant Pleural Mesothelioma, Melanoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Neuroendocrine Tumors, Non-Hodgkin Lymphoma, Parkinson's Disease, Peritoneal Cancer, Pneumoconiosis, Psychosis, Refractory Acute Myeloid Leukemia, Salivary Gland Cancer, Squamous Non-Small Cell Lung Cancer and Uterine Cancer.
Furthermore, this report also reviews key players involved in Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2)
- The report reviews Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Overview
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Companies Involved in Therapeutics Development
AbbVie Inc
AstraZeneca Plc
Boehringer Ingelheim International GmbH
Fratagene Therapeutics Srl
Lead Discovery Center GmbH
Onconova Therapeutics Inc
Prous Institute for Biomedical Research SA
TopiVert Ltd
Turning Point Therapeutics Inc
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Drug Profiles
bosutinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Inhibit SRC for Friedreich Ataxia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ilorasertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JRP-890 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nintedanib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ofev - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ON-150030 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
repotrectinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
saracatinib difumarate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Si-306 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit IGF1R and SRC for Non-Small Cell Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit SRC for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOP-1210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOP-1288 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOP-1630 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOP-1890 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPX-0022 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPX-0046 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Dormant Products
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Discontinued Products
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Jan 13, 2020: Clinical Trial will evaluate Saracatinib in Idiopathic Pulmonary Fibrosis
Nov 28, 2019: Health Canada approves Boehringer’s Ofev to slow SSc-ILD
Nov 19, 2019: New advances in the treatment of advanced lung cancer
Nov 12, 2019: Turning Point Therapeutics initiates phase 1/2 clinical study of Repotrectinib in pediatric patients
Nov 11, 2019: Turning Point Therapeutics initiates phase 1/2 clinical study of TPX-0046, a novel RET/SRC inhibitor
Nov 07, 2019: New analysis of patients with autoimmune-related ILDs in the INBUILD study shown as poster presentation at the 2019 ACR/ARP Annual Meeting
Oct 11, 2019: Boehringer’s nintedanib secures breakthrough status in US for ILDs
Oct 10, 2019: FDA grants Ofev breakthrough therapy designation for chronic fibrosing ILDs with a progressive phenotype
Oct 09, 2019: New data showed OFEV (nintedanib) slows decline of lung function in broad range of chronic fibrosing interstitial lung diseases with a progressive phenotype
Oct 01, 2019: Boehringer Ingelheim announces nintedanib trial met its primary endpoint
Sep 30, 2019: Nintedanib slows progression for broad range of scarring Lung Diseases
Sep 30, 2019: INBUILD meets primary endpoint - study evaluated nintedanib in patients across a range of progressive fibrosing interstitial lung diseases
Sep 30, 2019: Turning Point Therapeutics announces FDA clearance of Investigational New Drug Application for TPX-0046, a Novel RET/SRC Inhibitor
Sep 10, 2019: FDA approves Boehringer’s Ofev for rare lung disease
Sep 03, 2019: Turning Point Therapeutics announces updated preclinical Data for TPX-0046, a novel RET/SRC Inhibitor
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Overview
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Companies Involved in Therapeutics Development
AbbVie Inc
AstraZeneca Plc
Boehringer Ingelheim International GmbH
Fratagene Therapeutics Srl
Lead Discovery Center GmbH
Onconova Therapeutics Inc
Prous Institute for Biomedical Research SA
TopiVert Ltd
Turning Point Therapeutics Inc
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Drug Profiles
bosutinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Inhibit SRC for Friedreich Ataxia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ilorasertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JRP-890 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nintedanib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ofev - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ON-150030 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
repotrectinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
saracatinib difumarate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Si-306 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit IGF1R and SRC for Non-Small Cell Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit SRC for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOP-1210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOP-1288 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOP-1630 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOP-1890 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPX-0022 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPX-0046 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Dormant Products
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Discontinued Products
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Jan 13, 2020: Clinical Trial will evaluate Saracatinib in Idiopathic Pulmonary Fibrosis
Nov 28, 2019: Health Canada approves Boehringer’s Ofev to slow SSc-ILD
Nov 19, 2019: New advances in the treatment of advanced lung cancer
Nov 12, 2019: Turning Point Therapeutics initiates phase 1/2 clinical study of Repotrectinib in pediatric patients
Nov 11, 2019: Turning Point Therapeutics initiates phase 1/2 clinical study of TPX-0046, a novel RET/SRC inhibitor
Nov 07, 2019: New analysis of patients with autoimmune-related ILDs in the INBUILD study shown as poster presentation at the 2019 ACR/ARP Annual Meeting
Oct 11, 2019: Boehringer’s nintedanib secures breakthrough status in US for ILDs
Oct 10, 2019: FDA grants Ofev breakthrough therapy designation for chronic fibrosing ILDs with a progressive phenotype
Oct 09, 2019: New data showed OFEV (nintedanib) slows decline of lung function in broad range of chronic fibrosing interstitial lung diseases with a progressive phenotype
Oct 01, 2019: Boehringer Ingelheim announces nintedanib trial met its primary endpoint
Sep 30, 2019: Nintedanib slows progression for broad range of scarring Lung Diseases
Sep 30, 2019: INBUILD meets primary endpoint - study evaluated nintedanib in patients across a range of progressive fibrosing interstitial lung diseases
Sep 30, 2019: Turning Point Therapeutics announces FDA clearance of Investigational New Drug Application for TPX-0046, a Novel RET/SRC Inhibitor
Sep 10, 2019: FDA approves Boehringer’s Ofev for rare lung disease
Sep 03, 2019: Turning Point Therapeutics announces updated preclinical Data for TPX-0046, a novel RET/SRC Inhibitor
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by AbbVie Inc, H1 2020
Pipeline by AstraZeneca Plc, H1 2020
Pipeline by Boehringer Ingelheim International GmbH, H1 2020
Pipeline by Fratagene Therapeutics Srl, H1 2020
Pipeline by Lead Discovery Center GmbH, H1 2020
Pipeline by Onconova Therapeutics Inc, H1 2020
Pipeline by Prous Institute for Biomedical Research SA, H1 2020
Pipeline by TopiVert Ltd, H1 2020
Pipeline by Turning Point Therapeutics Inc, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Discontinued Products, H1 2020
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by AbbVie Inc, H1 2020
Pipeline by AstraZeneca Plc, H1 2020
Pipeline by Boehringer Ingelheim International GmbH, H1 2020
Pipeline by Fratagene Therapeutics Srl, H1 2020
Pipeline by Lead Discovery Center GmbH, H1 2020
Pipeline by Onconova Therapeutics Inc, H1 2020
Pipeline by Prous Institute for Biomedical Research SA, H1 2020
Pipeline by TopiVert Ltd, H1 2020
Pipeline by Turning Point Therapeutics Inc, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Discontinued Products, H1 2020
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
COMPANIES MENTIONED
AbbVie Inc
AstraZeneca Plc
Boehringer Ingelheim International GmbH
Fratagene Therapeutics Srl
Lead Discovery Center GmbH
Onconova Therapeutics Inc
Prous Institute for Biomedical Research SA
TopiVert Ltd
Turning Point Therapeutics Inc
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
COMPANIES MENTIONED
AbbVie Inc
AstraZeneca Plc
Boehringer Ingelheim International GmbH
Fratagene Therapeutics Srl
Lead Discovery Center GmbH
Onconova Therapeutics Inc
Prous Institute for Biomedical Research SA
TopiVert Ltd
Turning Point Therapeutics Inc
